This site uses cookies. By using this site you agree to receiving cookies. View Policy.
Successfully funded
/https://files-crowdcube-com.s3.amazonaws.com/files/pitch_pics/original/201903/blob_e99d4b6330627094077d6a7eab99aa77)
REPLICATE is here to change single tooth replacement with a patented, patient-friendly product that does not require drilling or destroying healthy teeth. Focus is the £18 billion tooth replacement market in the USA. Clinically validated in Europe, U.S. FDA filings are complete, awaiting approval.
- Unique, disruptive approach to single tooth replacement
- Raised over £17M from founders, VCs and crowd investors
- Clearance to sell in the EU
- Founders are serial entrepreneurs, sold last dental company to 3M
Idea
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201906/a1b172cce50c62cc9f85ba5acf9ba83b.jpg)
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201906/f14cf82ca36dcee8069a8ce43a8e3ce3.jpg)
:max_bytes(50000)/https://files-crowdcube-com.s3.amazonaws.com/files/opportunity_section_media/original/201906/2831210cad4de06d49227c3808844d67.jpg)
REPLICATE Dental Technologies PLC (RDT), based in Dublin, Ireland has developed, tested and refined a minimally-invasive, patented medical device for replacing teeth, part of the growing trend toward personalized medicine.
The REPLICATE Immediate Tooth Replacement System disrupts the £38 billion dental market in the UK, USA, EU, South Korea and Japan, currently dominated by three-unit dental bridges (13.2 million units, 7% CAGR) and traditional dental implant screws (3.5 million units, 5% CAGR).
Over the past 5 years, the Company has worked on clinically validating its product at selected sites in Europe but has not widely launched the REPLICATE System as the primary market is the retail dental segment in the U.S., representing approximately 50% of dollars spent globally on dental procedures. RDT filed a 510(k) pre-market notification with the U.S. Food and Drug Administration (FDA) and is awaiting regulatory approval to sell in the U.S.
To date, the Company has raised £17 million from founders, management, business angels, and venture capital firms in the U.S. and Europe. £2.4 million was raised on the German crowd investing platform Companisto.
The Company currently has operations in Berlin, Germany and Dallas, Texas, and underwent a restructuring in 2018, forming RDT as a holding company to prepare for capital market entry on EuroNext.
